Urovant Sciences Ltd. (UROV) Stock: Here’s What’s Happening

0

Urovant Sciences Ltd. (UROV) is falling in the market in today’s trading session. The stock, focused in the biotech space, is presently trading at $11.00 after tumbling -5.50% so far today. When it comes to biotechnology stocks, there are quite a few aspects that have the potential to generate price movement in the market. One of the most common is news. Here are the recent stories centered around UROV:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 04:09PM Here’s Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data
08:00AM Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
Mar-18-19 04:05PM Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
Mar-07-19 08:00AM Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
Mar-06-19 08:00AM Urovant Sciences Appoints James Robinson to its Board of Directors

However, any time investors are making an investing decision, prospective investors should look into far more than just news, especially in the highly speculative biotech industry. Here’s what’s happing when it comes to Urovant Sciences Ltd..

What We’ve Seen From UROV

While a decline in a single session, like the move that we’re seeing from Urovant Sciences Ltd. may cause fear in some investors, a single session decline by itself should not be the basis of a decision to, or not to, invest in a stock. It’s generally important to take a look at trends for a period longer than a single trading day. As it relates to UROV, here are the returns that we have seen:

  • Past Seven Days – In the past 7 days, UROV has produced a change in value in the amount of -20.00%.
  • Past 30 Days – The monthly ROI from Urovant Sciences Ltd. comes to 4.76%.
  • Past Quarter – Throughout the past three months, the stock has generated a return that comes to 105.22%
  • Bi-Annually – Over the last 6 months, investors have seen a performance that works out to 0 from the stock.
  • This Year So Far – Since the the first trading session of this year UROV has resulted in a ROI of 66.92%.
  • Full Year – Lastly, over the past full year, we’ve seen performance of 0 out of UROV. Throughout this period, the stock has traded at a high of -24.09% and a low price of 171.27%.

Key Ratios

Digging into a few key ratios associated with a stock can give prospective traders an understanding of just how risky and/or rewarding a stock pick might be. Below are a few of the key ratios to consider when looking at UROV.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the value of the stock is headed for declines. Across the sector, biotech stocks can come with a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, with regard to Urovant Sciences Ltd., the stock’s short ratio clocks in at 0.48.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Essentially, they measure whether or not a company can pay its debts when they mature based on current assets or quick assets. Because many biotech companies are reliant on continued investor support, the quick and current ratios can seem damning. However, some gems in the biotech industry do have good current and quick ratios. As it relates to UROV, the quick and current ratios come to 11.00 and 11.00 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the price of shares. In this case, that ratio works out to 3.38.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotech industry, this is an important ratio to consider. In this case, the cash to share value ratio is 3.23.

Analyst Opinions With Regard To Urovant Sciences Ltd.

While it’s never a good idea to unknowingly follow the opinions of analysts, it is a good idea to use their thoughts in order to validate your own due diligence when it comes to making investment decisions in the biotechnology industry. Here are the recent moves that we have seen from analysts as it relates to UROV.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-15-19 Initiated SunTrust Buy $24
Mar-11-19 Initiated H.C. Wainwright Buy $28
Oct-22-18 Initiated JP Morgan Overweight $21
Oct-22-18 Initiated Jefferies Buy $19

Is Big Money Interested In Urovant Sciences Ltd.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in UROV, here’s what we’re seeing:

Institutions own 22.80% of the company. Institutional interest has moved by -2.22% over the past three months. When it comes to insiders, those who are close to the company currently own 74.90% percent of UROV shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

A Look At Share Counts

Traders seem to be interested in the amounts of shares both available and outstanding. In regard to Urovant Sciences Ltd., there are currently 29.57M with a float of 7.62M. This means that of the total of 29.57M shares of UROV in existence today, 7.62M are able to trade hands on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to UROV, the short percent of the float is 0.43%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-3.96. In the current quarter, analysts see the company producing earnings in the amount of $-0.92. Over the last 5 years, UROV has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -85.10% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was developed by a human and human beings play a crucial role in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but, like humans, I am able to learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at information? If so, leave a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here